Department of Laboratory Medicine, University of California, San Francisco, California 94107, USA; email:
Department of Medicine, Division of Infectious Diseases, University of California, San Francisco, California 94107, USA.
Annu Rev Pathol. 2019 Jan 24;14:319-338. doi: 10.1146/annurev-pathmechdis-012418-012751. Epub 2018 Oct 24.
Nearly all infectious agents contain DNA or RNA genomes, making sequencing an attractive approach for pathogen detection. The cost of high-throughput or next-generation sequencing has been reduced by several orders of magnitude since its advent in 2004, and it has emerged as an enabling technological platform for the detection and taxonomic characterization of microorganisms in clinical samples from patients. This review focuses on the application of untargeted metagenomic next-generation sequencing to the clinical diagnosis of infectious diseases, particularly in areas in which conventional diagnostic approaches have limitations. The review covers ( a) next-generation sequencing technologies and common platforms, ( b) next-generation sequencing assay workflows in the clinical microbiology laboratory, ( c) bioinformatics analysis of metagenomic next-generation sequencing data, ( d) validation and use of metagenomic next-generation sequencing for diagnosing infectious diseases, and ( e) significant case reports and studies in this area. Next-generation sequencing is a new technology that has the promise to enhance our ability to diagnose, interrogate, and track infectious diseases.
几乎所有的传染性病原体都含有 DNA 或 RNA 基因组,因此测序成为一种很有吸引力的病原体检测方法。自 2004 年高通量或下一代测序技术问世以来,其成本已降低了几个数量级,并且已经成为在临床患者样本中检测和分类鉴定微生物的一种重要的技术平台。本文重点介绍了非靶向宏基因组下一代测序在传染病临床诊断中的应用,特别是在传统诊断方法存在局限性的领域。本文涵盖了以下几个方面:(a)下一代测序技术和常见平台;(b)临床微生物实验室中下一代测序检测工作流程;(c)宏基因组下一代测序数据的生物信息学分析;(d)宏基因组下一代测序在诊断传染病中的验证和应用;(e)该领域的重要病例报告和研究。下一代测序是一种新技术,有望提高我们诊断、探究和追踪传染病的能力。